Robert Zielinski

Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer

Ian D. Davis, Andrew Martin, Martin R. Stockler et al. · New England Journal of Medicine · 2019 · 1.6K citations

Pharmacy, Oncology, Pharmacotherapy +17

Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP

Martin R. Stockler, Andrew Martin, Ian D. Davis et al. · Journal of Clinical Oncology · 2021 · 60 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Updated overall survival outcomes in ENZAMET (ANZUP 1304), an international, cooperative group trial of enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC).

Ian D. Davis, Andrew Martin, Robert Zielinski et al. · Journal of Clinical Oncology · 2022 · 53 citations

Medicine, Oncology, Pharmacotherapy +17

Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy

Christopher J. Sweeney, Andrew Martin, Martin R. Stockler et al. · European Urology · 2021 · 48 citations

Medicine, Oncology, Urology +14

Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial

Maria De Santis, Joan Palou Redorta, Hiroyuki Nishiyama et al. · The Lancet · 2025 · 47 citations · Full text

Medicine, Oncology, Urology +13